endpoints.news is our new home on June 1. endpts.com will still work, but the front door is now https://endpoints.news

Pharma channel feed

Galera Ther­a­peu­tics to cut 70% of staff in wake of re­jec­tion for ra­dio­ther­a­py com­pli­ca­tion treat­ment

Last year
FDA+

Genen­tech, Blue­print tout full ap­proval for Gavre­to in rare type of lung can­cer

Last year
FDA+

More lab and man­u­fac­tur­ing space com­ing to the UK's 'Gold­en Tri­an­gle'

Last year
Manufacturing

Texas at­tor­ney gen­er­al an­nounces $42.7M set­tle­ment with Take­da, Bax­ter over AD­HD drug 

Last year
Law

Genen­tech adopts racial jus­tice lens for new fund­ing that goes be­yond typ­i­cal health eq­ui­ty grants

Last year
Marketing

OTC nalox­one nasal spray to cost about as much as the brand-name, pre­scrip­tion ver­sion

Last year

No­vavax plans to have up­dat­ed Covid vac­cine to mar­ket by Sep­tem­ber — but will it be ready in time?

Last year
Coronavirus

Evo­lus puts on 'y­outh­ful' new look for frown line treat­ment Jeu­veau

Last year
Marketing

Zyn­te­glo and Skysona com­bine for 16 pa­tient starts since ap­provals last year

Last year

Mar­ket­ingRx roundup: An­a­lyst group finds no ‘ob­vi­ous’ link to GLP-1s and sui­ci­dal ideation; Am­gen de­buts new Pro­lia TV ad

Last year
Marketing

Bris­tol My­ers in­tro­duces re­al pa­tients in dig­i­tal and so­cial So­tyk­tu pso­ri­a­sis cam­paign

Last year
Marketing

FDA's up­dat­ed rules for drug ad­ver­tis­ing for TV and ra­dio near the fin­ish line

Last year
Marketing

Up­dat­ed: Lil­ly's rev­enues rise 28% in Q2 thanks to surge in de­mand for di­a­betes drug Moun­jaro

Last year

Nek­tar sues Lil­ly, claim­ing its in­ter­est in biotech’s au­toim­mune drug ‘waned dra­mat­i­cal­ly’ af­ter buy­ing Der­mi­ra

Last year
Law

J&J inks an­oth­er Ste­lara biosim­i­lar set­tle­ment, push­ing Formy­con’s can­di­date in­to po­ten­tial 2025 launch

Last year

Hos­pi­tal groups ask Con­gress to re­form 340B pro­gram, crack down on con­tract phar­ma­cy re­stric­tions

Last year
FDA+

Vista­gen's pos­i­tive PhI­II for so­cial anx­i­ety nasal spray push­es stock price up 1,000+%

Last year

Vi­a­tris plans for Ozem­pic, We­govy gener­ics amid law­suit from No­vo Nordisk over We­govy

Last year

Ab­b­Vie dou­bles down on cor­po­rate aware­ness ef­forts in lat­est so­cial and dig­i­tal cam­paign

Last year
Marketing

Sage sug­gests job and pipeline cuts af­ter FDA re­jec­tion of ma­jor de­pres­sion pill

Last year
People
FDA+

Ac­er­a­gen to pull out of Nas­daq and liq­ui­date as­sets, end­ing tu­mul­tuous jour­ney for Idera Phar­ma

Last year
R&D

FDA ap­proves sec­ond ge­o­graph­ic at­ro­phy drug but caps use pe­ri­od, as Astel­las’ Iver­ic looks to spar with Apel­lis

Last year
FDA+

Up­dat­ed: FDA ap­proves Bio­gen and Sage's pill for post­par­tum de­pres­sion, but re­jects use in ma­jor de­pres­sion

Last year
R&D

Te­va agrees ‘in prin­ci­ple’ to $175M opi­oid set­tle­ment to hos­pi­tals and health sys­tems

Last year
Law
First page Previous page 108109110111112113114 Next page Last page
A service from the Financial Times